Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Radiologia (Engl Ed) ; 63(1): 13-21, 2021.
Article in English, Spanish | MEDLINE | ID: covidwho-1057313

ABSTRACT

INTRODUCTION: SARS-CoV-2, the virus responsible for the current pandemic, predominantly affects the respiratory tract, and a growing number of publications report the predisposition of patients with COVID-19 to develop thrombotic phenomena. OBJECTIVE: To determine the prevalence of pulmonary embolism in patients with COVID-19; to determine the possible relationship between the severity of pulmonary involvement and D-dimer levels; to analyze the location of pulmonary embolisms in patients with COVID-19 and to compare it with the location in patients without COVID-19. METHODS: This retrospective study analyzed all CT angiograms of the pulmonary arteries done in patients with suspected pulmonary embolisms between March 15 and April 30, 2020 and compared them with studies done in the same period one year earlier. RESULTS: We included 492 pulmonary CT angiograms (342 (69.9%) in patients with COVID-19 and 147 (30.1%) in patients without COVID-19). The prevalence of pulmonary embolisms was higher in patients with COVID-19 (26% vs. 16.3% in patients without COVID-19, p=0.0197; relative risk=1.6). The prevalence of pulmonary embolisms in the same period in 2019 was 13.2%, similar to that of the group of COVID-19-negative patients in 2020 (p=0.43). There were no significant differences in D-dimer levels or the location of pulmonary embolisms between the two groups. CT showed moderate or severe pulmonary involvement in 78.7% of the patients with COVID-19. CONCLUSIONS: Patients with COVID-19 have an increased prevalence of pulmonary embolisms (26%), and most (78.7%) have moderate or severe lung involvement on CT studies. The location of pulmonary embolisms and the degree of elevation of D-dimer levels does not differ between patients with COVID-19 and those without.


Subject(s)
COVID-19/complications , Pulmonary Embolism/epidemiology , Pulmonary Embolism/etiology , Adult , Aged , Aged, 80 and over , Computed Tomography Angiography , Female , Fibrin Fibrinogen Degradation Products/analysis , Humans , Male , Middle Aged , Prevalence , Pulmonary Embolism/blood , Pulmonary Embolism/diagnostic imaging , Retrospective Studies , Severity of Illness Index , Tertiary Care Centers
2.
Radiología (English Edition) ; 2021.
Article in English | ScienceDirect | ID: covidwho-1012540

ABSTRACT

Introduction SARS-CoV-2, the virus responsible for the current pandemic, predominantly affects the respiratory tract, and a growing number of publications report the predisposition of patients with COVID-19 to develop thrombotic phenomena. Objective To determine the prevalence of pulmonary embolism in patients with COVID-19;to determine the possible relationship between the severity of pulmonary involvement and d-dimer levels;to analyze the location of pulmonary embolisms in patients with COVID-19 and to compare it with the location in patients without COVID-19. Methods This retrospective study analyzed all CT angiograms of the pulmonary arteries done in patients with suspected pulmonary embolisms between March 15 and April 30, 2020 and compared them with studies done in the same period one year earlier. Results We included 492 pulmonary CT angiograms (342 (69.9%) in patients with COVID-19 and 147 (30.1%) in patients without COVID-19). The prevalence of pulmonary embolisms was higher in patients with COVID-19 (26% vs. 16.3% in patients without COVID-19, p = 0.0197;relative risk = 1.6). The prevalence of pulmonary embolisms in the same period in 2019 was 13.2%, similar to that of the group of COVID-19-negative patients in 2020 (p = 0.43). There were no significant differences in d-dimer levels or the location of pulmonary embolisms between the two groups. CT showed moderate or severe pulmonary involvement in 78.7% of the patients with COVID-19. Conclusions Patients with COVID-19 have an increased prevalence of pulmonary embolisms (26%), and most (78.7%) have moderate or severe lung involvement on CT studies. The location of pulmonary embolisms and the degree of elevation of d-dimer levels does not differ between patients with COVID-19 and those without. Resumen Introducción El coronavirus SARS-CoV-2, responsable de la pandemia actual, afecta preferentemente al tracto respiratorio, con un número creciente de publicaciones sobre su predisposición a fenómenos trombóticos. Objetivo Conocer la prevalencia de tromboembolismo pulmonar (TEP) en pacientes con COVID-19;determinar su posible relación con la gravedad de la enfermedad pulmonar y los niveles de dímeros-D, y analizar la localización del TEP en pacientes con COVID-19 comparándolos con los negativos. Método Estudio retrospectivo de todas las angio-TC de arterias pulmonares por sospecha de TEP del 15 de marzo al 30 de abril de 2020. Se compara con las angio-TC realizadas durante el mismo periodo en 2019. Resultados Se incluyeron 492 angio-TC pulmonares, 342 (69,9%) de pacientes con COVID-19 y 147 (30,1%) de pacientes sin infección. La prevalencia de TEP fue del 26% en el grupo COVID-19 positivo y del 16,3% en el negativo (p =  00,197), con un riesgo relativo de 1,6 veces. La prevalencia de TEP en el mismo período del año 2019 fue del 13,2%, similar a la del grupo COVID-19 negativo del año 2020 (p =  043). No hubo diferencias significativas en el nivel de dímeros D ni en la localización del TEP entre ambos grupos. El 78,7% de los pacientes con COVID-19 con TEP mostraron una extensión de la afectación pulmonar moderada o grave en la tomografía computarizada. Conclusiones Los pacientes con COVID-19 tienen una prevalencia aumentada de TEP (26%) y la mayoría (78,7%) presentan una extensión moderada o grave de afectación pulmonar en la tomografía computarizada. No hay diferencias significativas en la localización del material embólico ni en el grado de elevación de dímeros D respecto a los pacientes sin COVID-19.

3.
Radiologia (Engl Ed) ; 63(1): 56-73, 2021.
Article in English, Spanish | MEDLINE | ID: covidwho-989182

ABSTRACT

The pandemia caused by the SARS-CoV-2 virus has triggered an unprecedented health and economic crisis. Although the diagnosis of infection with SARS-CoV-2 is microbiological, imaging techniques play an important role in supporting the diagnosis, grading the severity of disease, guiding treatment, detecting complications, and evaluating the response to treatment. The lungs are the main organ involved, and chest X-rays, whether obtained in conventional X-ray suites or with portable units, are the first-line imaging test because they are widely available and economical. Chest CT is more sensitive than plain chest X-rays, and CT studies make it possible to identify complications in addition to pulmonary involvement, as well as to suggestive alternative diagnoses. The most common radiologic findings in COVID-19 are airspace opacities (consolidations and/or ground-glass opacities), which are typically bilateral, peripheral, and located primarily in the lower fields.


Subject(s)
COVID-19/diagnostic imaging , Radiography, Thoracic , Tomography, X-Ray Computed , Humans
SELECTION OF CITATIONS
SEARCH DETAIL